Organogenesis Holdings, Inc. (ORGO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

IRadimed Corp.

Organogenesis Holdings, Inc.

Outset Medical, Inc.

BioLife Solutions, Inc.

Mesa Laboratories, Inc.

Surmodics, Inc.

Orthofix Medical, Inc.

Castle Biosciences, Inc.

AirSculpt Technologies, Inc.

OraSure Technologies, Inc.

Minerva Surgical, Inc.

Why is Organogenesis Holdings, Inc. ?

High Management Efficiency with a high ROE of 15.16%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0 times

Healthy long term growth as Net Sales has grown by an annual rate of 9.76% and Operating profit at 8.21%

The company declared very negative results in Mar'25 after very positive results in Dec'24

PRE-TAX PROFIT(Q) At USD -9.87 MM has Fallen at -840.1%
NET PROFIT(Q) At USD -7.43 MM has Fallen at -316.95%
OPERATING CASH FLOW(Y) Lowest at USD -33.16 MM

With ROE of 3.72%, it has a risky valuation with a 1.05 Price to Book Value

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 30.69%, its profits have risen by 78.9% ; the PEG ratio of the company is 0.3

High Institutional Holdings at 57.8%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Their stake has increased by 1.82% over the previous quarter.

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Organogenesis Holdings, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Organogenesis Holdings, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Organogenesis Holdings, Inc.

23.93%

0.71

138.66%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

9.76%

EBIT Growth (5y)

8.21%

EBIT to Interest (avg)

8.26

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.28

Sales to Capital Employed (avg)

1.25

Tax Ratio

34.50%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

57.80%

ROCE (avg)

16.10%

ROE (avg)

15.16%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.05

EV to EBIT

52.77

EV to EBITDA

9.24

EV to Capital Employed

1.07

EV to Sales

0.62

PEG Ratio

0.32

Dividend Yield

ROCE (Latest)

2.03%

ROE (Latest)

3.72%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company

NO KEY POSITIVE TRIGGERS

-23What is not working for the Company

PRE-TAX PROFIT(Q)

At USD -9.87 MM has Fallen at -840.1%

NET PROFIT(Q)

At USD -7.43 MM has Fallen at -316.95%

OPERATING CASH FLOW(Y)

Lowest at USD -33.16 MM

RAW MATERIAL COST(Y)

Grown by 11.12% (YoY

INVENTORY TURNOVER RATIO(HY)

Lowest at 4.38 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 3.8 times

NET SALES(Q)

At USD 101 MM has Fallen at -11.93%

Here's what is working for Organogenesis Holdings, Inc.

Depreciation

Highest at USD 6.66 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Organogenesis Holdings, Inc.

Pre-Tax Profit

At USD -9.87 MM has Fallen at -840.1%

over average net sales of the previous four periods of USD 1.33 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -7.43 MM has Fallen at -316.95%

over average net sales of the previous four periods of USD 3.43 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -33.16 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Net Sales

At USD 101 MM has Fallen at -11.93%

over average net sales of the previous four periods of USD 114.69 MM

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Inventory Turnover Ratio

Lowest at 4.38 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 3.8 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 11.12% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales